Skip to content
Unrated Drug recall · FDA · Published December 16, 2025

Alembic Fesoterodine Tablets Recall: Diester Impurity Risk

Alembic Pharmaceuticals recalls 8mg extended-release fesoterodine tablets due to diester impurity levels exceeding safety limits. This may pose health risks for patients using prescription medication.

🇺🇸 FDA recall #D-0248-2026DrugAlembic Pharmaceuticals ›
Take action

Contact the company

Recalling firmAlembic Pharmaceuticals LimitedFormulation Division, Village Panelav, P.O. Tajpura, Near Baska, Taluka Halol · Panchmahal, India
✎ GovInfoNow plain-language explainer

Alembic Pharmaceuticals is recalling 8mg extended-release fesoterodine tablets because they contain diester impurities at levels above safe limits. This could potentially cause health issues for patients taking the medication as prescribed. Read more at govinfonow.com/recall/31614-alembic-fesoterodine-tablets-recall-diester-impurity-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31614-alembic-fesoterodine-tablets-recall-diester-impurity-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0248-2026

Cite this page

“Alembic Fesoterodine Tablets Recall: Diester Impurity Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31614-alembic-fesoterodine-tablets-recall-diester-impurity-risk. Based on FDA recall #D-0248-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0248-2026%22&limit=1).

The FDA announced on Dec. 16, 2025, that Alembic Pharmaceuticals Limited is recalling Fesoterodine Fumarate Extended-release Tablets, 8 mg, due to failed impurity specifications. The agency stated the recall is voluntary and ongoing.

How to tell if you have it

  • Brand: Alembic Pharmaceuticals
  • Product: Fesoterodine Fumarate, Extended-release Tablets, 8 mg, 30 Tablets
  • NDC: 62332-176-30
  • Lot#: 2405003360
  • Exp Date: Jan 31, 2026

The hazard

The recall is due to levels of 'Diester Impurity' exceeding the specification limit. The FDA's FAERS database contains 386 adverse-event reports naming this product, with 347 marked serious and 33 listing a death.

Context

GovInfoNow's records show Alembic Pharmaceuticals Limited has 6 other recalls on record since 2020-06-10. Other recent recalls of similar products include Alembic Fesoterodine Tablets Recall (2025-10-10), Alembic Doxepin Capsules Recall (2025-07-25), and Alembic Celecoxib Capsules 200mg Recall (2025-05-09). Other recent recalls of similar products include Zydus Mirabegron 25mg Tablets Recall (2026-08-05), Unichem Bisoprolol/Hydrochlorothiazide Tablets Recall (2026-01-21), and Sun Pharmaceutical Fexofenadine 180mg Tablets Recall (2026-06-01).

How to tell if you have this one

Check for the product name 'Fesoterodine Fumarate, Extended-release Tablets, 8 mg, 30 Tablets' with NDC 62332-176-30. The lot number is 2405003360 and expiration date is January 31, 2026.

  • Brand
    Alembic Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the product name, NDC number, and expiration date to confirm if your tablets are recalled.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “US Nationwide and PR.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 29 days after the firm started it.

1. Firm started the recall: Dec 16, 202512. FDA classified it Class III: Jan 2, 202623. Published in FDA’s Enforcement Report: Jan 14, 2026320252026
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0248-2026 (December 16, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0248-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA